ATE203413T1 - IMPFSTOFFE BESTEHEND AUS PROTEIN- ODER PEPTID- ßCOCHLEATENß UND DEREN VERWENDUNG ZUR IMMUNISIERUNG - Google Patents

IMPFSTOFFE BESTEHEND AUS PROTEIN- ODER PEPTID- ßCOCHLEATENß UND DEREN VERWENDUNG ZUR IMMUNISIERUNG

Info

Publication number
ATE203413T1
ATE203413T1 AT94930484T AT94930484T ATE203413T1 AT E203413 T1 ATE203413 T1 AT E203413T1 AT 94930484 T AT94930484 T AT 94930484T AT 94930484 T AT94930484 T AT 94930484T AT E203413 T1 ATE203413 T1 AT E203413T1
Authority
AT
Austria
Prior art keywords
peptide
protein
ßcochlatetenß
immunization
vaccines consisting
Prior art date
Application number
AT94930484T
Other languages
English (en)
Inventor
Susan Gould-Fogerite
Raphael James Mannino
Original Assignee
Albany Medical College
Univ New Jersey Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albany Medical College, Univ New Jersey Med filed Critical Albany Medical College
Application granted granted Critical
Publication of ATE203413T1 publication Critical patent/ATE203413T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6919—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a ribbon or a tubule cochleate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18834—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT94930484T 1993-10-04 1994-09-30 IMPFSTOFFE BESTEHEND AUS PROTEIN- ODER PEPTID- ßCOCHLEATENß UND DEREN VERWENDUNG ZUR IMMUNISIERUNG ATE203413T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/130,986 US5643574A (en) 1993-10-04 1993-10-04 Protein- or peptide-cochleate vaccines and methods of immunizing using the same
PCT/US1994/010913 WO1995009648A1 (en) 1993-10-04 1994-09-30 Protein- or peptide-cochleate vaccines and methods of immunizing using the same

Publications (1)

Publication Number Publication Date
ATE203413T1 true ATE203413T1 (de) 2001-08-15

Family

ID=22447349

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94930484T ATE203413T1 (de) 1993-10-04 1994-09-30 IMPFSTOFFE BESTEHEND AUS PROTEIN- ODER PEPTID- ßCOCHLEATENß UND DEREN VERWENDUNG ZUR IMMUNISIERUNG

Country Status (7)

Country Link
US (1) US5643574A (de)
EP (1) EP0722338B1 (de)
AT (1) ATE203413T1 (de)
AU (1) AU689505B2 (de)
CA (1) CA2169297C (de)
DE (1) DE69427824T2 (de)
WO (1) WO1995009648A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851536A (en) * 1995-11-22 1998-12-22 University Of Washington Therapeutic delivery using compounds self-assembled into high axial ratio microstructures
US6180114B1 (en) * 1996-11-21 2001-01-30 University Of Washington Therapeutic delivery using compounds self-assembled into high axial ratio microstructures
SE9604296D0 (sv) * 1996-11-22 1996-11-22 Astra Ab New pharmaceutical formulation of polypeptides
US6565889B2 (en) 1996-12-02 2003-05-20 The Regents Of The University Of California Bilayer structure which encapsulates multiple containment units and uses thereof
WO1998024415A1 (en) 1996-12-02 1998-06-11 The Regents Of The University Of California A bilayer structure which encapsulates multiple containment units and uses thereof
US6153217A (en) * 1999-01-22 2000-11-28 Biodelivery Sciences, Inc. Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents
US6274555B1 (en) 2000-05-15 2001-08-14 Lisa A. Berdami Composition and method for topical animal medication
CA2504329C (en) † 2002-11-01 2013-08-20 Biodelivery Sciences International, Inc. Geodate delivery vehicles
CU23313A1 (es) 2002-11-27 2008-09-25 Inst Finlay Ct De Investigacia Mã0/00todo de obtenciã"n de estructuras cocleares. composiciones vacunales y adyuvantes basados en estructuras cocleares y sus intermediarios
WO2004064805A1 (en) * 2003-01-15 2004-08-05 Biodelivery Sciences International, Inc. Cochleate preparations of fragile nutrients
WO2004091578A2 (en) 2003-04-09 2004-10-28 Biodelivery Sciences International, Inc. Novel encochleation methods, cochleates and methods of use
EP1631669A2 (de) 2003-04-09 2006-03-08 Biodelivery Sciences International, Inc. Gegen proteinexpression gerichtete cochleat-zusammensetzungen
US7663017B2 (en) 2003-07-30 2010-02-16 Institut Pasteur Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
EP1945253A2 (de) * 2005-11-04 2008-07-23 Novartis Vaccines and Diagnostics S.r.l. Verabreichungswege zum primen/boosten von grippeimpfstoffen
TW200833709A (en) 2006-12-15 2008-08-16 Ca Nat Research Council Archaeal polar lipid aggregates for administration to animals
WO2012151517A1 (en) 2011-05-05 2012-11-08 Coordinated Program Development, Llc Cochleate compositions and methods of making and using same
CU20110202A7 (es) 2011-11-02 2013-12-27 Inst Finlay Ct De Investigación Producción De Sueros Y Vacunas Composición inmunogénica de polisacáridos planos adyuvados y las formulaciones resultantes
EP2689775A1 (de) 2012-07-25 2014-01-29 Instituto Finlay, Centro de Investigacion-Produccion de vacunas y sueros Cochlea mit nur einem mikrobenassoziierten Molekularmuster (MAMP)
KR20180004104A (ko) * 2015-03-03 2018-01-10 마티나스 바이오파마 나노테크놀로지스, 인코포레이티드 코클레이트 및 약리학적 활성제의 조직 침투를 향상시키기 위해 이를 사용하는 방법
KR101989789B1 (ko) 2017-11-30 2019-06-18 (주) 에이치엔에이파마켐 포스파티딜세린/음이온계면활성제/염화칼슘을 이용한 코킬레이트
WO2024039733A1 (en) 2022-08-16 2024-02-22 Matinas Biopharma Nanotechnologies, Inc. Methods of controlling lipid nanocrystal particle size and lipid nanocrystals produced by such methods
WO2024039729A1 (en) 2022-08-16 2024-02-22 Matinas Biopharma Nanotechnologies, Inc. Antifungal agent encapsulated in a lipid nanocrystal for treating mucormycosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4078052A (en) * 1976-06-30 1978-03-07 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Large unilamellar vesicles (LUV) and method of preparing same
US4871488A (en) * 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles
US4663161A (en) * 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions

Also Published As

Publication number Publication date
EP0722338A1 (de) 1996-07-24
DE69427824D1 (de) 2001-08-30
US5643574A (en) 1997-07-01
EP0722338A4 (de) 1999-04-14
EP0722338B1 (de) 2001-07-25
DE69427824T2 (de) 2002-04-11
AU7959094A (en) 1995-05-01
CA2169297C (en) 2005-08-02
WO1995009648A1 (en) 1995-04-13
AU689505B2 (en) 1998-04-02
CA2169297A1 (en) 1995-04-13

Similar Documents

Publication Publication Date Title
ATE203413T1 (de) IMPFSTOFFE BESTEHEND AUS PROTEIN- ODER PEPTID- ßCOCHLEATENß UND DEREN VERWENDUNG ZUR IMMUNISIERUNG
EP0855918A4 (de) Interleukin-15 aus hühnern und seine verwendungen
DK0853487T3 (da) Neutraliserende monoklonale antistoffer mod respiratorisk syncytial virus
ATE267258T1 (de) Impfstoffe für das respiratorische-synzytial- virus mit nuklein säuren
ATE61228T1 (de) Immunogener protein- oder peptidkomplex, verfahren zur herstellung dieses komplexes und seine verwendung als immunstimulans und als impfstoff.
DE69129989D1 (de) Arzneimittelzusammensetzung zur behandlung oder vorbeugung maligner tumore
DE68924162D1 (de) Stressproteine und verwendungen dafür.
CY1107571T1 (el) Αυξητικος παραγοντας νευρων ως βοηθητικη ουσια εμβολιου
EP0400958A3 (de) Lebende Impfstoffe
FI102382B1 (fi) Ilmentämisjärjestelmä ihmisen respiratory syncytial -viruksen glykoproteiinien immunogeenisia fragmentteja sisältäviä kimeerisiä glykoproteiineja varten
CA2290696A1 (en) Immunopotentiating composition
DE69637523D1 (de) Chimäre antikörper zur abgabe von antigenen an selektierte zellen des immunsystems
DE68918673D1 (de) IgG-bindendes Protein H, kodierendes Gen dafür und Verfahren zu seiner Herstellung.
WO1995024481A3 (en) Humanized monoclonal antibodies against human interleukin-4
DE69940692D1 (de) Verwendung von immunogenen immunsuppressiven und/oder angiogenen proteinen die inaktiviert sind, verfahren zur deren herstellung, und verwendungen als pharmazeutikum oder impfstoff
ATE73349T1 (de) Hepatitisoberflaechenantigenpartikelvakzin.
DE69030099D1 (de) Verfahren zur herstellung von impfstoffen oder toxoiden
DE68916424D1 (de) Pasteurella-impfstoff.
Lopez-Merino et al. Immunization by an insoluble fraction extracted from Brucella melitensis: immunological and chemical characterization of the active substances
ATE420951T1 (de) Schützende epitope von adenylate-zyklase- hämolysin(ac-hly) und ihre verwendung zur behandlung oder verhütung von bordetella- infektionen
DE69429521D1 (de) Zusammensetzung und verfahren zur stimulation der reproduzierenden leistung
Hauer Purification and characterization of Clostridium perfringens type C beta toxin
IT1276765B1 (it) Gene del cromosoma x umano e proteina codificata da detto gene.
DK230890A (da) Dna-fragment, der koder for et pasteurella multocida-toxin eller for en subsekvens eller analog deraf, ekspressionsvektor, der omfatter dna-fragmentet, mikroorganisme, der udtrykker dette, fremgangsmaade til fremstilling af et pasteurella-multocida-toxin, diagnostisk middel samt anvendelse heraf, vaccine indeholdende et pasteurella-multocida-toxinderivat, anvendelse af pasteurella multocida-t m.m.
MX9709525A (es) Vacunas de virus sincicial respiratorio de acido nucleico.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification